Lack of Research Stymies Uptake of Medical Marijuana for Rheumatic Pain An interesting read from @CreakyJoints. Check it out our synopsis. https://t.co/dHlUrWcyjB https://t.co/pL5Sn5eD7h

Comparison of NHANES survey data from 2 eras (2007–2008 and 2017–2018) shows that prevalence blood pressure control decreased from 65% to 55% over 10 yrs(P=0.03); while lipid control remained stable; and diabetes med use rose 71% to 95% https://t.co/WIWBCYo2Yi https://t.co/mS7uVIiyUq

Small RCT 39 pts with #PMR given tocilizumab or placebo. Steroid-free remission at wk 16 was 64% on tocilizumab (63.2%) and 12% placebo. Mean time to first relapse was shorter with PBO (82 vs 130days). 5 SAE PBO, 1 TCZ https://t.co/5tomZsaaU6 https://t.co/yAMGY5nlCU

Evobrutinib, selective oral BTK inhibitor, has been studied in >1083 pts in phase 3 RCTs of RA, SLE, MS; shows well tolerated, most common AE ≥5% UTI (9.5%), nasopharyngitis (7.3%), diarrhea (6.2%), transient ^LFTs, SIE rate 2.72/100 PYs https://t.co/NTKYOAHhln https://t.co/oUKCDicjyA

Acne with JAK Inhibitors JAK inhibitors have become enormously popular and while their side effect profile has been delineated and reviewed, little mention is made of acne – an adverse event that may affect up to one-quarter of patients taking JAKi. https://t.co/b9pX9NgZAx https://t.co/RL9vi3Xbf6

Prospective randomized trial of ultrasound-guided genicular nerve block (GNB) vs physical therapy (PT) i102 pts chronic knee #OA - GNB was superior at walk distance, pain, functional and physical capacity, at 12 weeks https://t.co/MOJ16zAiqH https://t.co/JJJye2dobH

Expansive (full read) review of CBD - legal and regulatory overview, availability, physiologic and pharmacologic effects, safety, & risks, standards, use in specific rheumatic disorders. https://t.co/hefwKTmPLK https://t.co/IZKZMOZ5ij

TOMORROW! Register for our 5/10 Tuesday Night Rheumatology on PsA Advances. This webinar will feature highlights from: PsA Guidelines Arthur Kavanaugh, MD Drug Targeting in PsA Bruce Kirkham, MD PsA Registries and Real World Data Alexis Ogdie, MD https://t.co/0fNuHz6wVy https://t.co/KssNJ41Wqz

Allopurinol Use Does Not Increase Mortality in Gout w/ Chronic Kidney Disease A trial has shown that allopurinol use dose escalation and achieving target uric acid levels, was not associated w/ increased mortality in patients with gout and concurrent CKD. https://t.co/8LHlRyTgS0 https://t.co/4Hu9cTwptO

Hyperuricemia as a biomarker of severe #PsA? Study of 242 PsA pts 30% had hyperuricemia & 6% had gout. Hyperuricemia was significantly associated with age, comorbidity, perph polyarthritis, Jt destruction, less response to treatment. https://t.co/U5wAQdWLdC https://t.co/QfoaogDeun